Welcome to our dedicated page for Personalis SEC filings (Ticker: PSNL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the story behind Personalis’ next genomic breakthrough can mean digging through hundreds of pages of SEC text. Our dedicated Personalis filings page turns that task into a focused research session. Start with the Personalis insider trading Form 4 transactions feed to see executive stock moves the moment they post. Curious about the company’s cash runway? The Personalis quarterly earnings report 10-Q filing section lets you jump straight to burn-rate tables, while our AI tags any changes in customer concentration.
Every document—10-K, 10-Q, 8-K, DEF 14A—is parsed by Stock Titan’s AI engine. Instead of wrestling with dense genomics jargon, you get plain-English call-outs like “new pharma partnership disclosed” or “R&D expense up 12%.” That means Personalis SEC filings explained simply and ready for quick decision-making.
Need real-time alerts? Enable the Personalis Form 4 insider transactions real-time toggle and get notified before markets open. For deep dives, open the Personalis annual report 10-K simplified view: our AI groups risk factors on reimbursement, CLIA compliance, and intellectual-property challenges so you can scan what matters. You can also:
- Compare quarter-over-quarter revenue trends with our Personalis earnings report filing analysis
- Review Personalis proxy statement executive compensation highlights to assess incentive alignment
- Browse Personalis 8-K material events explained for trial data releases or major contracts
- Download raw exhibits when you need full context
Whether you’re understanding Personalis SEC documents with AI for a fast pitch deck or tracking Personalis executive stock transactions Form 4 for sentiment signals, this page delivers every filing the instant it hits EDGAR—already summarized, already searchable.
Personalis (PSNL) announced that its ultrasensitive NeXT Personal tests received Medicare coverage for post‑treatment surveillance of cancer recurrence in stage II and III breast cancer. The determination from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program is effective retroactively as of October 7, 2025.
The NeXT Personal Dx Breast MRD Recurrence Monitoring Test is covered at a reimbursement rate of $3,878 and is available once per cancer diagnosis. The NeXT Personal Single Plasma Test is covered at $1,158 and is available for up to six years post‑treatment. This expands access and establishes defined payment levels for these assays among eligible Medicare patients.
Personalis, Inc. (PSNL) reported an insider transaction by its President and CEO. On 11/03/2025, the reporting person sold 29,612 shares of common stock at a weighted average price of $8.99, with individual sale prices ranging from $8.78 to $9.56. The filing states the shares were automatically sold to cover tax withholding from the settlement of vested restricted stock units. Following the transaction, the reporting person beneficially owned 148,486 shares directly.
Personalis, Inc. reported Q3 results and liquidity updates. Revenue was
Year‑to‑date revenue was
Customer concentration remained significant, including contributions from Moderna, Regeneron and Pfizer in the period. The Tempus commercialization agreement continued, with
Personalis, Inc. (PSNL) furnished an 8-K under Item 2.02 announcing it issued a press release with financial results for the quarter ended September 30, 2025.
The full text of the release is provided as Exhibit 99.1 and is incorporated herein by reference. The information, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other Securities Act or Exchange Act filings except as expressly set forth by specific reference.
Amendment No. 2 to a Schedule 13D reports that Tempus AI, Inc. beneficially holds 12,718,800 shares of Personalis common stock, representing 14.3% of the outstanding shares based on 88,677,062 shares outstanding. Tempus acquired 9,218,800 shares by exercising warrants for $18,437,600 and purchased 3,500,000 shares from the issuer at $5.07 per share, funded from working capital.
The filing notes that Eric Lefkofsky, as controlling stockholder of Tempus, may be deemed to beneficially own the Tempus-held shares and directly holds 150,000 additional shares, bringing his aggregate to 12,868,800 shares (about 14.5%). The parties amended their Commercialization Agreement to permit Tempus to make open-market purchases up to 19.99% provided other standstill terms are met. A copy of Amendment No. 5 is filed as an exhibit.
Personalis, Inc. (PSNL) filed a Form S-8 to register 350,000 additional common shares (par $0.0001) for issuance under its 2020 Inducement Plan. The filing, made on 5 Aug 2025, brings the total shares available for equity awards to new hires under this Nasdaq-compliant plan up from prior registrations (May 2020 & May 2023) by incorporating those earlier S-8 statements.
The company is classified as a non-accelerated filer and smaller reporting company; therefore, the registration relies on simplified disclosure. No proceeds flow to the company—shares will be issued as restricted stock units or stock options to attract and retain talent. While the aggregate amount is modest (<2% of the 20.4 m shares outstanding at 30 Jun 2025), it adds minor dilution potential and increases equity-based compensation expense over time.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
